Leukemogenesis by CBF oncoproteins

Leukemia

Volumn 13, Issue 12, 1999, Pages 1932-1942

  Friedman, A D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AML1 ETO; AML1 MDS1 EVI1; CBF; CBF SMMHC; TEL AML1

Indexed keywords

HYBRID PROTEIN; ONCOPROTEIN;

ACUTE LYMPHOCYTIC LEUKEMIA; B CELL LEUKEMIA; CHROMOSOME TRANSLOCATION; HUMAN; LEUKEMOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032760819     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401590     Document Type: Review

References (186)

1. Kamachi Y, Ogawa E, Asano M, Ishida S, Murakami Y, Satake M, Ito Y, Shigesda K. Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. Mol Cell Biol 1990; 64; 4808-4819.
2. Wang S, Speck NA. Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Mol Cell Biol 1992; 12: 89-102.
3. Bae S-C, Yamaguchi-Iwai Y, Ogawa E, Maruyama M, Inuzuka M, Kagoshima H, Shigesada K, Satake M, Ito Y. Isolation of PEBP2αB cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene 1993; 8: 809-814.
4. Ogawa E, Maruyama M, Kagoshima H, Inuzuka M, Lu J, Satake M, Shigesada K, Ito Y. PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosphila runt gene and the human AML1 gene. Proc Natl Acad Sci USA 1993; 90: 6859-6863.
5. Ogawa E, Inuzuka M, Maruyamna M, Satake M, Naito-Fujimoto M, Ito Y, Shigesada K. Molecular cloning and characterization of PEBP2β, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2α. Virology 1993; 194: 314-331.
6. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. AML1, 2 and 3. The human members of the runt domain gene-family. Genomics 1994; 23: 425-432.
7. Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 1993; 13: 3324-3339.
8. Bae S-C, Ogawa E, Maruyama M, Oka H, Satake M, Shigesada K, Jenkins NA, Gilbert DJ, Copeland NC, Ito Y. PEBP2αB/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials. Mol Cell Biol 1994; 14: 3242-3252.
9. Zhang Y-W, Bae S-C, Huang G, Fu Y-X, Lu FJ, Ahn M-Y, Kanno Y, Kanno T, Ito Y. A novel transcript encoding an N-terminally truncated AML1/PEBP2αB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells. Mol Cell Biol 1997; 17: 4133-4145.
10. Golling G, Li L-H, Pepling M, Stebbins M, Gergen J. Drosophila homologs of the proto-oncogene product PEBP2/CBFβ regulate the DNA-binding properties of runt. Mol Cell Biol 1996; 16: 932-942.
11. Kagoshima H, Akamatsu Y, Ito Y, Shigesada K. Functional dissection of the α and β subunits of transcription factor PEBP2 and the redox susceptibility of its DNA binding activity. J Biol Chem 1996; 271: 33074-33082.
12. Kania MA, Bonner AS, Duffy JB, Gergen JP. The Drosophila segmentation gene runt encodes a novel nuclear regulatory protein that is also expressed in the developing nervous system. Genes Dev 1990; 4: 1701-1713.
13. Meyers S, Downing JR, Hiebert SW. Identification of AML1 and the (8;21) translocation protein AML1-ETO as sequence specific DNA binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 1993; 13: 6336-6345.
14. Lenny N, Meyers S, Hiebert SW. Functional domains of the t(8:21) fusion protein, AML1-ETO. Oncogene 1995; 11: 1761-1759.
15. Akamatsu Y, Tsukumo S, Kagoshima H, Tsurushita N, Shigesada K. A simple screening for mutant DNA binding proteins: application to murine transcription factor PEBP2α subunit, a founding member of the Runt domain protein family. Gene 1997; 185; 111-117.
16. Crute BE, Lewis AF, Wu Z, Bushweller JH, Speck NA. Biochemical and biophysical properties of the core-binding factor α2 (AML1) DNA-bindmg domain. J Biol Chem 1996; 271: 26251-26260.
17. Melnikova IN, Crute BE, Wang S, Speck NA. Sequence specificity of the core-binding factor. J Virol 1993; 67: 2408-2411.
18. Suzow J, Friedman AD. The murine myeloperoxidase promoter contains several functional elements - one element binds a cell type-restricted transcription factor, myeloid nuclear factor 1 (MyNF1). Mol Cell Biol 1993; 13: 2141-2151.
19. Redondo JM, Pfohl JL, Hernandez-Munain C, Wang S, Speck NA, Krangel MS. Indistinguishable nuclear factor binding to functional core sites ol the T-cell receptor δ and murine leukemia virus enhancers. Mol Cell Biol 1992; 12: 4817-4823.
20. Cameron S, Taylor DS, TePas EC, Speck NA, Mathey-Privot B. Identification of a critical regulator site in the human interleukin-3 promoter by in vivo footprinting. Blood 1994; 83: 2851-2859.
21. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2β/CBFβ oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol 1994; 14: 5558-5568.
22. Zhang D-E, Fujioka K-I, Hetherington CJ, Shapiro LH, Chen H-M, Look AT, Tenen DG. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol 1994; 14: 8085-8095.
23. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 1995; 11: 2667-2674.
24. Hernandez-Munain C, Krangel MS. Regulation of the T-cell receptor δ enhancer by functional cooperation between c-Myb and core binding factors. Mol Cell Biol 1994; 14: 473-483.
25. Sun W, Graves BJ, Speck NA. Transactivation of the Moloney murine leukemia virus and T-cell receptor β-chain enhancers by cbf and ets requires intact binding sites for both proteins. J Virol 1995; 69: 4941-4949.
26. Giese K, Kingsley C, Kirshner JR, Grosschedl R. Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. Genes Dev 1995; 9: 995-1008.
27. Zaiman AL, Lenz J. Transcriptional activation of a retroviral enhancer by CBF (AML1) requires a second factor: evidence for cooperation with c-Myb. J Virol 1996; 70: 5618-5629.
28. Zhang D-E, Hetherington CJ, Meyers S, Rhoades KL, Larson CJ, Chen HM, Hiebert SW, Tenen DG. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBFα2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol 1996; 16: 1231-1240.
29. Britos-Bray M, Friedman AD. Core binding factor (CBF) cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol Cell Biol 1997; 17: 5127-5135.
30. Petrovick MS, Hiebert SW, Friedman AD, Hetherington CJ, Tenen DG, Zhang D-E. Multiple functional domains of AML1: PU.1 and C/EBPα synergize with different regions of AML1. Mol Cell Biol 1998; 18: 3915-3925.
31. Wotton D, Ghysdael J, Wang S, Speck NA, Owen MJ. Cooperative binding of ets-1 and core binding factor to DNA. Mol Cell Biol 1994; 14: 840-850.
32. Hernandez-Munain C, Krangel MS. C-myb and core-binding factor/PEBP2 display functional synergy but bind independently to adjacent sites in the T-cell receptor δ enhancer. Mol Cell Biol 1995; 15: 3090-3099.
33. Bruhn L, Munnerlyn A, Grosschedl R. ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRα enhancer function. Genes Dev 1997; 11: 640-653.
34. Kitbayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the luekemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 1998; 17: 2994-3004.
35. Yagi R, Chen L-F, Shigesada K, Murakami Y, Ito Y. A WW domam-containg Yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999; 18: 2551-2562.
36. Kanno T, Kanno Y, Chen L-F, Ogawa E, Kim W-Y, Ito Y. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor α subunit revealed in the presence of the β subunit. Mol Cell Biol 1998; 18: 2444-2454.
37. Kim W-Y, Sieweke M, Ogawa E, Wee H-J, Englmeier U, Graf T, Ito Y. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J 1999; 6: 1609-1620.
38. Manoukina AS, Krause HM. Control of segmental asymmetry in Drosophila embryos. Development 1993; 118: 785-796.
39. Tsai C, Gergen JP. Gap gene properties of the pair-rule gene runt during Drosophila segmentation. Development 1994; 120: 1671-1683.
40. Aronson BD, Fisher AL, Blechman K, Caudy M, Gergen JP. Groucho-dependent and -independent repression activities of runt domain proteins. Mol Cell Biol 1997; 17: 5581-5587.
41. Imai Y, Kurokawa M, Tanaka K, Friedman AD, Ogawa S, Mitani K, Yazaki Y, Hirai H. TLE, the human homolog of groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation. Biochem Biophys Res Commun 1998; 252: 582-589.
42. Levanon D, Goldstein RE, Bernstein Y, Tang H, Goldenberg D, Stifani S, Paroush Z, Groner Y. Transcriptional repression by AML1 and LEF-1 is mediated by TLE/groucho corepressers. Proc Natl Acad Sci USA 1998; 95: 11590-11595.
43. Ahn M-Y, Huang G, Bae S-C, Wee H-J, Kim W-Y, Ito Y. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32D cl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO(MTG8). Proc Natl Acad Sci USA 1998; 95: 1812-1817.
44. Lutterbach B, Westendorf JJ, Linggi B, Hiebert SW. AML-1, a target of multiple chromosomal translocations in acute leukemia, interacts with mSin3 to repress transcription from the p21/WAF1/CIP1 promoter. Blood 1998; 92: 508a.
45. Satake M, Inuzuka M, Shigesada K, Oikawa T, Ito Y. Differential expression of subspecies of polyomavirus and murine leukemia virus enhancer core binding protein, PEBP2, in various hematopoietic cells, Jpn J Cancer Res 1992; 83: 714-722.
46. Erickson P, Dessev G, Lasher RS, Philips G, Robinson M, Drabkin H. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 1996; 88: 1813-1823.
47. Tanaka T, Kurokawa M, Ueki K, Tanaka K, Imai Y, Mitani K, Okazaki K, Sagata N, Yazaki Y, Shibata Y, Kadowaki T, Hirai H. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol 1996; 16: 3967-3979.
48. Zeng C, van Wijnen AJ, Stein JL, Meyers S, Sun W, Shopland L, Lawrence JB, Penman S, Lian JB, Stein GS, Hiebert SW. Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-α transcription factors, Proc Natl Acad Sci USA 1998; 94: 6746-6751.
49. Satake M, Nomura S, Yamaguchi-Iwai Y, Takahama Y, Hashimoto Y, Niki M, Kitamura Y, Ito Y. Expression of the runt domain-encoded PEBP2α genes in T cells during thymic development. Mol Cell Biol 1995; 15: 1662-1670.
50. Meyers S, Lenny N, Hiebert SW. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia. Oncogene 1996; 13: 303-312.
51. Corsetti MT, Calabi F. Lineage-and stage-specific expression of runt box polypeptides in primitive and definitive hematopoiesis. Blood 1997; 89: 2359-2368.
52. Simeone A, Daga A, Calabi F. Expression of runt in the mouse embryo. Dev Dyn 1995; 203: 61-70.
53. North T, Gu T-L, Stacy T, Wang Q, Howard L, Binder M, Marin-Padilla M, Speck NA. Cbfa2 is required for the formation of intraaortic hematopoietic clusters. Development 1999; 126: 2563-2575.
54. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML-1, the target of multiple chromosomal translocations in human leukemia, is essential for normal murine fetal hematopoiesis. Cell 1996; 84: 321-330.
55. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996; 93: 3444-3449.
56. Wang Q, Stacy T, Miller JD, Lewis AF, Gu T-L, Huang X, Bushweller JH, Bories J-C, Alt FW, Ryan G, Liu PP, Wynshaw-Boris A, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. The CBFβ subunit is essential for CBFα2 (AML1) function in vivo. Cell 1996; 87: 697-708.
57. Sasaki K, Yagi H, Bronson RT, Tominaga K, Matsunashi T, Deguchi K, Tani Y, Kishimoto T, Komori T. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor β. Proc Natl Acad Sci USA 1996; 93; 12359-12363.
58. Niki M, Okada H, Takano H, Kujo J, Tani K, Hibino H, Asano S, Ito Y, Satake M, Noda T. Hematopoiesis in the fetal liver is impaired by the targeted mutagenesis of the gene encoding a non-DNA binding subunit of the transcription factor, PEBP2/CBF. Proc Natl Acad Sci USA 1997; 94: 5697-5702.
59. Lu J, Maruyama M, Satake M, Bae S-C, Ogawa S, Kagoshima H, Shigesada K, Ito Y. Subcellular localization of the α and β subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF. Mol Cell Biol 1995; 15: 1651-1661.
60. Tanaka Y. Watanabe T, Chiba N, Niki M, Kuroiwa Y, Nishihira, Satomi TS, Ito Y, Satake M. The protooncogene product, PEBP2/CBFβ, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures. Oncogene 1997; 15: 677-683.
61. Liu P, Tarle SA, Hajre A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS. Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041-1044.
62. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene. Proc Natl Acad Sci USA 1991; 88: 10431-10434.
63. Erickson P, Gao J, Chang K-S, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarities to Drosophila segmentation gene, runt. Blood 1992; 80: 1825-1831.
64. Nisson PE, Watkins PC, Sacchi N. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. Cancer Genet Cytogenet 1992; 63: 81-88.
65. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993; 12: 2715-2721.
66. Erickson PF, Robinson M, Owens G, Drabkin HA. The ETO portion of AML t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Cancer Res 1994; 54: 1782-1786.
67. Nucifora G, Begy CR, Erickson P, Drabkin HA, Rowley JD. The 8;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER1. Proc Natl Acad Sci USA 1993; 90: 7784-7788.
68. Mitani K, Ogawa S, Miyoshi H, Mano H, Yazaki Y, Ohki M, Hirai H. Generation of the AML1/Evi-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis of chronic myelocytic leukemia. EMRO J 1994; 13: 504-510.
69. Sacchi N, Nisson PE, Watkins PC, Faustinella F, Wijsman J, Hagemeijer A. AML1 fusion transcripts in t(3;21) positive leukemia. Evidence of molecular heterogeneity and usage of splicing sites frequently involved in the generation of normal AML1 transcripts. Genes Chromosom Cancer 1994; 11: 226-256.
70. Roulston D, Espinosa R III, Nucifora G, Larson RA, LeBeau MM, Rowley JD. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood 1998; 92: 2879-2885.
71. Gamou T, Kitamura E, Hosada F. Shimizu K, Shinohara K, Hayashi Y, Nagase T, Yokoyama Y, Ohki M. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood 1998; 91: 4028-4037.
72. Golub TR, Barker GF, Bohlander SK, Hiebert S, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in ALL. Proc Natl Acad Sci USA 1995; 92: 4917-4922.
73. Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995; 85: 3662-3670.
74. Shurtleff SA, Meyers S, Hiebert SW, Raimondi SC, Head Dr, Willman CL, Wolman S, Slovak ML, Carroll AJ, Behm F, Hulshof MG, Motroni TA, Okuda T, Liu P, Collins FS. Downing JR. Heterogeneity in CBFβ/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood 1995; 85: 3695-3703.
75. Claxton D, Xie Q-S, Patel S, Deisseroth AB, Kornblau S. The gene product ot CBFB-MYH11. Leukemia 1996; 10: 1479-1485.
76. Liu PP, Wijmenga C, Hajra A, Blake TB, Kelley CA, Adelstein RS, Baggf A, Rector J, Cotelingam J, Willman CL, Collins FS. Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells. Genes Chromosom Cancer 1996; 16: 77-87.
77. Liu PP, Seidel N, Bodine D, Speck NA, Tarle S, Collins FS. Acute myeloid leukemia with inv(16) produces a chimeric transcription factor with a myosin heavy chain tail. CSH Symp Quant Biol 1994; 59: 547-553.
78. Yanagisawa M, Hamada Y, Katsuragawa Y, Imamura M, Mikawa T, Masaki T. Complete primary structure of vertebrate smooth muscle myosin heavy chain deduced from its complementary DNA sequence. J Mol Biol 1987; 198: 143-157.
79. Nagai R, Kuro M, Babij P, Periasamy M. Identification of two types of smooth muscle myosin heavy chain isoforms by cDNA cloning and immunoblot analysis. J Biol Chem 1998; 264: 9734-9737.
80. Hodge TP, Cross R, Kendrick-Jones J. Role of the COOH-terminal nonhelical tailpiece in the assembly of a vertebrate nonmuscle myosin rod. J Cell Biol 1992; 118: 1085-1095.
81. Cao W, Britos-Bray M, Claxton DF, Kelley CA, Speck NA, Liu PP, Friedman AD. CBFβ-SMMHC, expressed in M4eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene 1997; 15: 1315-1327.
82. Wijmenga C, Gregory PE, Hajra A, Schrock E, Ried T, Eils T, Liu PP, Collins FS. CBFβ-SMMHC chimeric protein involved in AML forms unusual nuclear rod-like structures in transformed NIH 3T3 cells. Proc Natl Acad Sci USA 1996; 93: 1630-1635.
83. Kanno Y, Kanno T, Sakakura C, Bae S-C, Ito Y. Cytoplasmic sequestration of the polyomavirus enhancer binding protein (PEBP2)/core binding factor (CBFα) subunit by the leukemia-related PEBP2/CBFβ-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol 1998; 18: 4252-4261.
84. Adya N, Stacy T, Speck NA, Liu PP. The leukemic protein core binding factor beta (CBFβ)-smooth muscle myosin heavy chain sequesters CBFα2 into cytoskeletal filaments and aggregates. Mol Cell Biol 1998; 18: 7432-7443.
85. Tanaka Y, Fujii M, Hayashi K, Chiba N, Akaishi T, Shineha R, Nishihira T, Satomi S, Ito Y, Watanabe T, Satake M. The chimeric protein, PEBP2β/CBFβ-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation. Oncogene 1998; 17: 699-708.
86. Cao W, Adya N, Britos-Bray M, Liu PP, Friedman AD. The core binding factor α interaction domain and the smooth muscle myosin heavy chain segment of CBFβ-SMMHC are both required to slow cell proliferation. J Biol Chem 1998; 47: 31534-31540.
87. Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. The t(8;21) fusion product, AML1-ETO, associates with C/EBPα, inhibits C/EBPα-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 1998; 18: 322-333.
88. Castilla LH, Wijmenga C, Stacy T, Speck NA, Eckhaus M, Marin-Padilla M, Collins FS, Wynshaw-Boris A, Liu PP. Failure of embryonic heamatopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 1996; 87: 687-696.
89. Kogan SC, Lagasse E, Atwater S, Bae SC, Weissman I, Ito Y, Bishop JM. The PEBP2βMYH11 fusion created by inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci USA 1998; 95: 11863-11868.
90. Strom D, Westendorf J, Lenny N, Nip J, Lutterbach B, Downing JR, Hiebert SW. Overexpression of AML-1B shortens the G1 phase of the cell cycle. Blood 1997; 90: 570a.
91. Lou J, Cao W, Ayyanathan K, Rauscher FJ III, Friedman AD. CBF oncoproteins slow the G1 to S phase cell cycle transition by decreasing cdk4 RNA levels. Blood 1998; 92: 215a.
92. Castilla LH, Bodine DM, Garrett L, Liu PP. Leukemia development by the induction of a second 'hit' in chimeric mice containing Cbfβ-MYH11 ES cells. Blood 1998; 92: 214a.
93. Britos-Bray M, Ramirez M, Cao W, Wang X, Liu PP, Friedman AD. CBFβ-SMMHC, expressed in M4eo AML, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents. Blood 1998; 92: 4344-4352.
94. Sacchi N, Schiaffonati L, Magnani I, Pappalardo C, Hughes AJ Jr, Darfler M, Hoogeveen AT. Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia. Oncogene 1996; 12: 437-444.
95. Le X-F, Claxton D, Kornblau S, Fan Y-H, Mu Z-M, Chang K-S. Characterization of the ETO and AML1-ETO proteins involved in the 8;21 translocation in acute myelogenous leukemia. Eur J Haematol 1998; 60: 217-225.
96. Tanaka K, Tanaka T, Kurokawa M, Imai Y, Ogawa S, Hiebert SW, Mitani K, Yazaki Y, Hirai H. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2β(CBFβ) in the nucleus more efficiently than wild-type AML1. Blood 1998; 91: 1688-1699.
97. Tighe JE, Calabi F. Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative(8) chromosome in t(8;21) of acute myeloid leukemia M2. Blood 1994; 84: 2115-2121.
98. Britos-Bray M, Sacchi N, Friedman AD. The DNA-binding domain of AML1, expressed in t(8:21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 320 cl3 myeloid cells. Leukemia 1996; 10: 984-990.
99. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1 B-dependent transcriptional activation. Mol Cell Biol 1995; 15: 1974-1982.
100. Lutterbach B, Sun D, Schuetz J, Hiebert SW. The MYND motif is required for suppression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol Cell Biol 1998; 18: 3604-3611.
101. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860-10865.
102. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. ETO, a target of t(8;21) in acute leukemia, interacts with N-CoR and mSin3 corepressors. Mol Cell Biol 1998; 18: 7176-7184.
103. Gelmetti V, Zhang J, Fanelli M, Minucci S. Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18: 7185-7191.
104. Kitbayashi I, Ida K, Morohoshi F, Yokoyama A, Mitsuhashi N, Shimizu K, Nomura N, Hayashi Y, Ohki M. The AML1-MTG8 leukemia fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol 1998; 18: 846-858.
105. Yergeau DA, Hetherington CJ, Wang Q, Zhang P. Sharpe AH, Binder M, Marin-Padilla M, Tenen DG. Speck NA, Zhang D-E. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997; 15: 303-306.
106. Okuda T, Cai Z, Yang S, Lenny N, Lyu C, van Deursen MA, Harada H, Downing JR. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998; 91: 3134-3143.
107. Rhoades KL, Hetherington CJ, Rowley JD, Hiebert SW, Nucifora G, Tenen DG, Zhang D-E. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci USA 1996; 93: 11895-11900.
108. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci USA 1996; 93: 14059-14064.
109. Liu L-Q, Ilaria R Jr, Kingsley PD, Iwama A, van Etten RA, Palis J, Zhang D-E. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1/ETO-expressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 1999; 19: 3029-3038.
110. Feinstein PG, Kornfeld K, Hogness DS, Mann RS. Identification of homeotic target genes in Drosophila melanogaster including nervy, a proto-oncogene homologue. Genetics 1995; 140: 573-586.
111. Era T, Asou N, Yamaguchi K, Yamasaki H, Kamada N, Nishikawa S-I, Takatsuki K. Expression of AML1 and ETO transcripts in hematopoietic cells. Leukemia 1995; 9: S26-S28.
112. Era T, Asou N, Kunisada T, Yamasaki H, Asou H, Kamada N, Nishikawa S-I, Yamaguchi K, Takatsuki K. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells. Genes Chromosom Cancer 1995; 13: 25-33.
113. Sacchi N, Tamanini F, Willemsen R, Denis-Donini S, Campiglio S, Hoogeveen AT. Subcellular localization of the oncoprotein MTG8 (CDR/ETO) in neural cells. Oncogene 1998; 16: 2609-2515.
114. Davis JN, Williams BJ, Herron JT, Galiano FJ, Meyers S. ETO-2, a new member of the ETO-family of nuclear proteins. Oncogene 1999; 18: 1375-1383.
115. Maurer AB, Ottmann OG, Heidenreich O, Heil G, Ganser A, Grez M, Hoelzer D. The t(8;21) fusion protein, AML1/ETO, blocks differentiation and increases sensitivity to IL-3 in the factor-dependent cell line TF-1. Leukemia 1997; 11: 2230.
116. Sakakura C, Yamaguchi-Iwai Y, Satake M, Bae S-C, Takahashi A, Ogawa E, Hagiwara A, Takahashi T, Murakami A, Makino K, Nakagawa T, Kamada N, Ito Y. Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide. Proc Natl Acad Sci USA 1994; 91: 11723-11727.
117. Rodel JE, Link DC. Suppression of apoptosis during cytokine deprivation of 32D cells is not sufficient to induce complete granulocytic differentiation. Blood 1996; 87: 858-864.
118. Kohzaki H, Ito K, Huang G, Wee H-J, Murakami Y, Ito Y. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed bcl-2. Oncogene 1999 (in press).
119. Wang X, Scott E, Sawyers CL, Friedman AD. C/EBPα by-passes G-CSF signals to rapidly induce PU. 1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999; 94: 560-571.
120. Timchenko NA, Wilde M, Darlington GJ. C/EBPα regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice. Mol Cell Biol 1999; 19: 2936-2945.
121. Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene 1999, 18; 1701-1710.
122. Wang J, Wang M, Liu JM. Transformation properties of the ETO gene, fusion partner in t(8;21) leukemias. Cancer Res 1997; 57: 2951-2955.
123. Sueoka E, Sueoka N, Okabe S, Komor A, Suganuma M, Kozu T, Fujiki H. Tumourigenicity of MTG8, a leukaemia-related gene, in concert with v-Ha-ras gene in BALB/3T3 cells. Br J Haematol 1998; 101: 737-742.
124. Kurokawa M, Tanaka T, Tanaka K, Ogawa S, Mitani K, Yazaki Y, Hirai H. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene 1996; 12: 883-892.
125. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82: 712-715.
126. Chang K-S, Fan Y-H, Stass SA, Estey EH, Wang G, Trujillo JM, Erickson P, Drabkin H. Expression of AMLI-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene 1993; 8: 983-988.
127. Downing JR, Head DR, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ, Drabkin HA, Willman C, Theil KS, Civin CI, Erickson P. An AMLI/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8:21)(q22;q22) translocation. Blood 1993; 81: 2860-2865.
128. Kusec R, Laczika K, Knobl P. Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purstscher B, Haas OA, Lechner K, Jaeger U. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994; 8: 735-739.
129. Nucifora G, Begy CR, Kubayashi H, Claxton D, Pederson-Bjergaard J, Paraganas E, Ihle JN, Rowley JD. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q21 and unrelated genes at 3q26 in (3;21)(q26:q22) translocations. Proc Natl Acad Sci USA 1994; 91: 4004-4008.
130. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 1996; 93: 1642-1647.
131. Soderholm J, Kobayashi H, Mathieu C, Row-ley JD, Nucifora G. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia 1997; 11: 352-358.
132. Matsugi T, Morishita K, Ihle JN. Identification, nuclear localization, and DNA-binding activity of the zinc finger protein encoded by the Evi-1 myeloid transforming gene. Mol Cell Biol 1990; 10: 1259-1264.
133. Lopingco MC, Perkins AS. Molecular analysis of Evi1, a zinc linger oncogene involved in myeloid leukemia. Curr Topics Microb Immunol 1996; 211: 211-222.
134. Perkins AS, Fishel R, Jenkins NA, Copeland NG. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence specific DNA-binding protein. Mol Cell Biol 1991; 11: 2665-2674.
135. Delwel R, Funabiki T, Kreider BL, Morishita K, Ihle JN. Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required tor sequence specific binding to GA(C/T)AAGA (T/C)AAGATAA. Mol Cell Biol 1993; 13: 4291-4300.
136. Perkins AS, Kim JH. Zinc fingers 1-7 of EVI1 fail to bind to the GATA motif by itself but require the core site GACAAGATA for binding. J Biol Chem 1996; 271: 1104-1110.
137. Funabiki T, Kreider BL, Ihle JN. The carboxyl domain of zinc fingers of the Evi-1 myeloid transforming gene binds a consensus sequence GAAGATGAG. Oncogene 1994; 9: 1575-1581.
138. Kreider BL, Orkin SH, Ihle JN. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transtorming gene. Proc Natl Acad Sci USA 1993; 90: 6454-6458.
139. Bartholomew C, Kilbey A, Clark A-M, Walker M. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene 1997; 14: 569-577.
140. Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y, Hirai H. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 1994; 269: 24020-24026.
141. Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, Gamer LW, Potter SS, Ihle JN, Mucenski ML. The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mechan Dev 1997; 65: 55-70.
142. Morishita K, Parganas E, Willman CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB, Ihli JN. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992; 89: 3937-3941.
143. Fichelson S, Dreyfus F, Berger R, Melle J, Bastard C, Miclea JM, Gisselbrech S. Evi-1 expression in leukemic patients with rearrangements of the 3q25-q28 chromosomal region. Leukemia 1992; 6: 93-99.
144. Levy ER, Parganas E, Morishita K, Fichelson S, James L, Oscier D, Gisselbrecht S, Ihle JN, Buckle VJ. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. Blood 1994; 83: 1348-1354.
145. Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, Ihle JN, Taetle R. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84: 1243-1248.
146. Morishita K, Parganas E, Matsugi T, Ihle JN. Expression of the Evi-1 zinc finger gene in 32D cl3 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol 1992; 12: 183-189.
147. Khanna-Gupta A, Lopingco MC, Savinelli T, Zibello T, Berliner N, Perkins AS. Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dc13. Oncogene 1996; 12: 563-569.
148. Tanaka T, Mitani K, Kurokawa M, Ogawa S, Tanaka K, Nishida J, Yazaki Y, Shibata Y, Hirai H. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Mol Cell Biol 1995; 15: 2383-2392.
149. Zent CS, Mathieu C, Claxton DF, Zhang DE, Tenen DG, Rowley JD, Nucifora G. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoting properties. Proc Natl Acad Sci USA 1996; 93: 1044-1048.
150. Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. The t(3;21) fusion product, AML1/EVi1, interacts with Smad3 and blocks transforming growth factor-β-mediated growth inhibition of myeloid cells. Blood 1998; 92: 4003-4012.
151. Sood R, Trikha-Talwar A, Chakrabarti SR, Nucifora G. MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, hut the leukemia-associated fusion protein AML1/MDS1/EVI1, product of t(3;21), abrogates growth-inhibition in response to TGF-β1. Leukemia 1999; 13: 348-357.
152. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H. The oncoprotein Evi-1 represses TCP-beta signalling by inhibiting Smad3. Nature 1998; 394: 92-96.
153. Baruchel A, Cayuela JM, Ballerini P, Landman-Parker J, Cezard V, Firat H, Haddad E, Auclerc MF, Valensi F, Cayre YE, Macintyre EA, Sigaux F. The majority of myeloid-antigen-positive (My+) childhood B-cell precursor ALLs express TEL-AML1 fusion transcripts, Br J Haematol 1997; 99: 101-106.
154. Uphoff CC, MacLeod RAF, Denkmann SA, Golub TR, Borkhardt A, Janssen JWG, Drexler HG. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines. Leukemia 1997; 11: 1220-1223.
155. Kwong YL, Wong KF. Low frequency of TEL/AML1 in adult acute lymphoblastic leukemia. Cancer Genet Cytogenet 1997; 98: 137-138.
156. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
157. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A, Downing JR, Grosveld G, Roussel MF, Gilliland DG, Lenny N, Meyers S. The t(12;21) translocation converts AML1-1B from an activator to a repressor of transcription. Mol Cell Biol 1996; 16: 1349-1355.
158. Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene 1999; 18: 1015-1022.
159. Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J, Guidal-Giroux C, Guo C, Vilmer E, Marynen P, Grandchamp B. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996; 87: 2891-2899.
160. Kim D-H, Moldwin RL, Vignon C, Bohlander SK, Suto Y, Giordano L, Gupta R, Fears S, Nucifora G, Rowley JD, Smith SD. TEL-AML1 translocations with TEL and CDKN2 inactivation in ALL cell lines. Blood 1996; 88: 685-794.
161. Takeuchi S, Seriu T, Bartram CR, Golub TR, Reitner A, Miyoski I, Gilliland DG, Koeffler HP. TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia. Leukemia 1997; 11: 1220-1223.
162. Wlodarska I, La Starza R, Baens M, Dierlamm Uyttebroeck JA, Selleslag D, Francine A, Mecucci C, Hagemeijer A, Van den Berghe J, Marynen P. Fluorescence in situ hybridization characterization of new translocations involving TEL (ETV6) in a wide spectrum of hematologic malignancies. Blood 1998; 91: 1399-1406.
163. Poirel HC, Oury C, Carron C, Duprez E, Laabi Y, Tsapis A, Romana SR, Mauchauffe M, Le Coniat M, Berger R, Ghysdael J, Bernard OA. The TEL gene products: nuclear phosphoproteins with DNA binding properties. Oncogene 1996; 14: 349-357.
164. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, Koeffler HP, Takeuche S, Janssen JWG, Seriu T, Bartram CR, Sallan SE, Gilliland DG, Golub TR. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood ALL. Blood 1996; 88: 4252-4258.
165. Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O, Ghysdael J. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRβ oncoprotein. EMBO J 1997; 16: 69-82.
166. Kwiatkowski BA, Bastian LS, Bauer TR Jr, Tsai S, Zielinska-Kwiatkowska AG, Hickstein DD. The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity. J Biol Chem 1998; 273: 17525-17530.
167. Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, Orkin SH. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking Ets-related factor TEL. EMBO J 1997; 16: 4374-4383.
168. Wang LC, Swat W, Fujiwara Y, Davison L. Visvader J, Kuo F, Alt FW, Gilliland DG, Golub TR, Orkin SH. Definitive hematopoietic defects in chimeric mice lacking the ETS-relaled factor TEL. Genes Dev 1998; 12: 2392-2402.
169. Rubnitz JE, Pui C-H, Downing JR. The role of TEL fusion genes in pediatric leukemias. Leukemia 1999; 13: 6-13.
170. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesda K, Ito Y. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias. Blood 1999; 93: 1817-1824.
171. Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JWG, Reiter A, Ludwig W-D, Zimmermann M, Schwaller J, Lee E, Miyoshi I, Koeffler HP. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphocytic leukemia of childhood. Blood 1995; 86: 755-766.
172. Okuda T, Shurtleff SA, Valentine MB, Raimondi SC, Head DR, Behm F, Curcio-Brint AM, Liu Q, Pui CH, Sherr CJ, Beach D, Look AT, Downing JR. Frequent deletion of p16INK4a/MTS1 and p15/INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995; 85: 2321-2330.
173. Herman JG, Jen Merlo JA, Baylin SB. Hyper-methylation-associated inactivation indicates a tumor suppressor role for p15(INK4B1). Cancer Res 1996; 56: 722-727.
174. Stegmaier K, Pendse S, Barker GF, Bray-Ward P, Ward DC, Montgomery KT, Krauter KS, Reynolds C, Sklar J, Donnelly M, Bohlander SK, Rowley JD, Sallan SE, Gilliland DG, Golub TR. Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 38-44.
175. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
176. Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 1995; 9: 600-611.
177. Imamura J, Miyoshi I, Koeffler P. p53 in hematologic malignancies. Blood 1994; 84: 2412-2421.
178. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 1998; 391: 811-814.
179. Da Silva N, Meyer-Monard S, Bastie J-N, Domhret H, Degos L, Chomienne C. G-CSF induced STAT1 and STAT3 kinetics of activation are normal in G-CSF sensitive t(8;21) AML cells. Leukemia 1997; 11: 2225.
180. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
181. Neil JC, Terry SA, Hu M, O'Hara M, Blyth K, Baxter E, Cameron E, Onions DE. Activation of PEBP2αA (CBFA1) by retroviral insertion: a new myc collaborating oncogene? Leukemia 1997; 11: 2231.
182. Mao, S, Frank RC, Zhang J, Miyazaki Y, Nimer SD. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol Cell Biol 1999; 19: 3635-3644.
183. Samuels BL, Larson RA, Le Beau MM, Daly KM, Bitter MA, Vardiman JW, Barker CM, Rowley JD, Golomb HM. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 1988; 2: 79-83.
184. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173-4179.
185. Rubnitz JE, Shuster JJ, Land FJ, Link MP, Pullen DJ, Camitta BM, Pui C-H, Downing JR, Behm FG. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a pediatric oncology group study. Blood 1997; 89: 1143-1146.
186. Smith BD, Bambach BJ, Vala MS, Barber JP, Enger C, Brodsky RA, Burke PJ, Gore SD, Jones RJ. Inhibited apoptosis and drug resistance in acute myeloid leukemia. Br J Haematol 1998; 102: 1042-1049.